Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/adma.202405690 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Purpose: This study evaluates the efficacy of intravitreal injections (IVI) of faricimab in patients with neovascular age-related macular degeneration (nAMD) and retinal pigment epithelium detachment (RPED) resistant to other anti-VEGF agents.
Material And Methods: The study included 61 patients (61 eyes) with nAMD previously treated with aflibercept and/or brolucizumab IVIs. Three groups were formed: group 1 received aflibercept IVI (32 eyes), group 2 received brolucizumab IVI (14 eyes), and group 3 received aflibercept followed by brolucizumab IVI (15 eyes).
Masseter muscle thickness before and after the correction of unilateral functional posterior crossbite in growing individuals: a prospective controlled clinical trial.
Eur J Orthod
December 2024
Division of Orthodontics, University Clinics of Dental Medicine, University of Geneva, 1 rue Michel-Servet, 1205 Geneva, Switzerland.
Objectives: To evaluate whether unilateral functional posterior crossbite in growing children creates an asymmetry in masseter muscle thickness and whether this asymmetry is normalized after crossbite correction.
Materials And Methods: Two groups of growing individuals were studied prospectively: (i) a treatment group: children with unilateral functional posterior crossbite, undergoing crossbite correction with maxillary expansion; and (ii) a control group: children without transversal malocclusions and orthodontic treatment. The thickness of the masseter muscles was measured bilaterally using ultrasonographic recordings at three time points: pre-treatment (T0); 9 months after (T1); and 30 months after posterior crossbite correction (T2); and at equivalent time points in the control group.
Evaluation of Facial Aesthetic Changes in Growing Class II Patients Treated with Herbst or Elastodontics: A Retrospective Study.
Dent J (Basel)
December 2024
Department of Clinical Medicine, Public Health, Environmental Life Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
The objective of this study was to evaluate the facial profile changes of patients treated for class II skeletal malocclusions with an elastodontic appliance compared to those treated with the Herbst appliance and a control group. Forty class II patients were treated using an elastodontic appliance (Group EA) and were compared to 40 patients treated with the Herbst appliance (Group H) and to 40 untreated class II children (Group C). Aesthetic profile variables were analysed using Arnett's analysis.
View Article and Find Full Text PDFA Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer.
Invest New Drugs
December 2024
Division of Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Antiangiogenic drugs may cause vascular normalization and correct hypoxia in tumors, shifting cells to mitochondrial respiration as the primary source of energy. In turn, the addition of an inhibitor of mitochondrial respiration to antiangiogenic therapy holds potential to induce synthetic lethality. This study evaluated the mitochondrial inhibitor ME-344 in combination with bevacizumab in patients with refractory metastatic colorectal cancer (mCRC).
View Article and Find Full Text PDFFavorable outcomes of patients with high-risk uveal melanoma treated with a novel LINAC-based frameless fractionated stereotactic radiosurgery.
Am J Ophthalmol
December 2024
Department of Radiation Oncology, Thomas Jefferson University, Philadelphia PA. Electronic address:
Purpose: Uveal melanoma (UM) represents the most prevalent and aggressive intraocular malignancy in adults. This study examined the outcomes of patients diagnosed with high-risk UM who underwent fractionated stereotactic radiosurgery (fSRS) treatment utilizing a novel LINAC-based frameless technique.
Design: Retrospective, interventional case series.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!